These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 10849091)

  • 1. Validation of immunolocalization of the urokinase receptor expression in ductal carcinoma in situ of the breast: comparison with detection by non-isotopic in-situ hybridization.
    Hildenbrand R; Leitz M; Magdolen V; Luther T; Albrecht S; Graeff H; Stutte HJ; Bleyl U; Schmitt M
    Histopathology; 2000 Jun; 36(6):499-504. PubMed ID: 10849091
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Urokinase receptor localization in breast cancer and benign lesions assessed by in situ hybridization and immunohistochemistry.
    Hildenbrand R; Glienke W; Magdolen V; Graeff H; Stutte HJ; Schmitt M
    Histochem Cell Biol; 1998 Jul; 110(1):27-32. PubMed ID: 9681686
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The urokinase-system in tumor tissue stroma of the breast and breast cancer cell invasion.
    Hildenbrand R; Schaaf A
    Int J Oncol; 2009 Jan; 34(1):15-23. PubMed ID: 19082473
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Stromal cells associated with early invasive foci in human mammary ductal carcinoma in situ coexpress urokinase and urokinase receptor.
    Nielsen BS; Rank F; Illemann M; Lund LR; Danø K
    Int J Cancer; 2007 May; 120(10):2086-95. PubMed ID: 17290405
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Urokinase plasminogen activator system gene expression is increased in human breast carcinoma and its bone metastases--a comparison of normal breast tissue, non-invasive and invasive carcinoma and osseous metastases.
    Fisher JL; Field CL; Zhou H; Harris TL; Henderson MA; Choong PF
    Breast Cancer Res Treat; 2000 May; 61(1):1-12. PubMed ID: 10930085
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Plasminogen activator system localization in 60 cases of ductal carcinoma in situ.
    Hurd TC; Sait S; Kohga S; Winston J; Martinick M; Saxena R; Lankes H; Markus G; Harvey S; Gibbs JF
    Ann Surg Oncol; 2007 Nov; 14(11):3117-24. PubMed ID: 17701256
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Urokinase plasminogen activator receptor (CD87) expression of tumor-associated macrophages in ductal carcinoma in situ, breast cancer, and resident macrophages of normal breast tissue.
    Hildenbrand R; Wolf G; Böhme B; Bleyl U; Steinborn A
    J Leukoc Biol; 1999 Jul; 66(1):40-9. PubMed ID: 10410988
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Protein and mRNA expression of uPAR and PAI-1 in myoepithelial cells of early breast cancer lesions and normal breast tissue.
    Hildenbrand R; Arens N
    Br J Cancer; 2004 Aug; 91(3):564-71. PubMed ID: 15226768
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tissue distribution of soluble and receptor-bound urokinase in human breast cancer using a panel of monoclonal antibodies.
    Carriero MV; Franco P; Del Vecchio S; Massa O; Botti G; D'Aiuto G; Stoppelli MP; Salvatore M
    Cancer Res; 1994 Oct; 54(20):5445-54. PubMed ID: 7923178
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Differential gene expression of urokinase-type plasminogen activator and its receptor in human renal cell carcinoma.
    Bhuvarahamurthy V; Schroeder J; Kristiansen G; Roigas J; Denkert C; Johannsen M; Lein M; Loening SA; Schnorr D; Jung K; Staack A
    Oncol Rep; 2005 Sep; 14(3):777-82. PubMed ID: 16077991
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Epitope-mapped monoclonal antibodies as tools for functional and morphological analyses of the human urokinase receptor in tumor tissue.
    Luther T; Magdolen V; Albrecht S; Kasper M; Riemer C; Kessler H; Graeff H; Müller M; Schmitt M
    Am J Pathol; 1997 Apr; 150(4):1231-44. PubMed ID: 9094980
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tumor stroma is the predominant uPA-, uPAR-, PAI-1-expressing tissue in human breast cancer: prognostic impact.
    Hildenbrand R; Schaaf A; Dorn-Beineke A; Allgayer H; Sütterlin M; Marx A; Stroebel P
    Histol Histopathol; 2009 Jul; 24(7):869-77. PubMed ID: 19475533
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combined overexpression of urokinase, urokinase receptor, and plasminogen activator inhibitor-1 is associated with breast cancer progression: an immunohistochemical comparison of normal, benign, and malignant breast tissues.
    Costantini V; Sidoni A; Deveglia R; Cazzato OA; Bellezza G; Ferri I; Bucciarelli E; Nenci GG
    Cancer; 1996 Mar; 77(6):1079-88. PubMed ID: 8635127
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Loss of the expression of the tumor suppressor gene ARHI is associated with progression of breast cancer.
    Wang L; Hoque A; Luo RZ; Yuan J; Lu Z; Nishimoto A; Liu J; Sahin AA; Lippman SM; Bast RC; Yu Y
    Clin Cancer Res; 2003 Sep; 9(10 Pt 1):3660-6. PubMed ID: 14506155
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Urokinase receptor-associated protein (uPARAP) is expressed in connection with malignant as well as benign lesions of the human breast and occurs in specific populations of stromal cells.
    Schnack Nielsen B; Rank F; Engelholm LH; Holm A; Danø K; Behrendt N
    Int J Cancer; 2002 Apr; 98(5):656-64. PubMed ID: 11920633
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Progression-specific genes identified in microdissected formalin-fixed and paraffin-embedded tissue containing matched ductal carcinoma in situ and invasive ductal breast cancers.
    Schultz S; Bartsch H; Sotlar K; Petat-Dutter K; Bonin M; Kahlert S; Harbeck N; Vogel U; Seeger H; Fehm T; Neubauer HJ
    BMC Med Genomics; 2018 Sep; 11(1):80. PubMed ID: 30236106
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Messenger RNA for urokinase plasminogen activator is expressed in myofibroblasts adjacent to cancer cells in human breast cancer.
    Nielsen BS; Sehested M; Timshel S; Pyke C; Danø K
    Lab Invest; 1996 Jan; 74(1):168-77. PubMed ID: 8569179
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In situ gene expression of urokinase-type plasminogen activator and its receptor in transitional cell carcinoma of the human bladder.
    Bhuvarahamurthy V; Schroeder J; Denkert C; Kristiansen G; Schnorr D; Loening SA; Jung K; Staack A
    Oncol Rep; 2004 Oct; 12(4):909-13. PubMed ID: 15375521
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Endothelial and macrophage upregulation of urokinase receptor expression in human renal cell carcinoma.
    Xu Y; Hagege J; Doublet JD; Callard P; Sraer JD; Ronne E; Rondeau E
    Hum Pathol; 1997 Feb; 28(2):206-13. PubMed ID: 9023404
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The role of HER2/neu overexpression/amplification in the progression of ductal carcinoma in situ to invasive carcinoma of the breast.
    Latta EK; Tjan S; Parkes RK; O'Malley FP
    Mod Pathol; 2002 Dec; 15(12):1318-25. PubMed ID: 12481013
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.